



September 10<sup>th</sup>, 2012

VRL/SEC/BSE/91

Dept. of Corporate Services  
The Stock Exchange, Mumbai  
25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai

**Sub. : Venus Remedies Bags First Patent From Canada For VANCOPPLUS**

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has secured its first patent from Canada for its novel antibiotic adjuvant entity "VANCOPPLUS". The patent has been granted by the Canadian patent office and is valid up to May 2027. The company is planning to launch the product in Canada in the next two years.

The company is really enthusiastic over the receipt of this Canadian patent for VANCOPPLUS, which will prove to be a fertile ground for the success of this product not just commercially but also in terms of catering to the constantly rising Methicillin Resistant Staphylococcus Aureus (MRSA) infection rates in Canada.

As per a research report published by Canadian Antimicrobial Resistance Alliance (CARA), the community acquired MRSA cases have increased significantly from 19.5% in 2007 to 38.1% in 2010. Various studies and surveys conducted in Canada state that almost 40% of the MRSA cases have arisen from the community with increase in MRSA infection amongst children and young adults who have no hospital contact or exposure.

There is a dramatic rise in the number of cases of Canadians getting infected by MRSA both in hospitals and within communities. Discussing more about this patent. At this time of need Vancoplus seems to be the only effective and safe option to curb the notorious MRSA strain. As the Canadian pharmaceutical market is the 3<sup>rd</sup> fastest growing market globally, shows the great growth potential for R&D players in the industry to create better drugs to curb such diseases. With this patent, Venus is hopeful of capturing a significant share in the Canadian Pharmaceutical market.

VANCOPPLUS is an 'Antibiotic Adjuvant Entity' (AAE) constituting Ceftriaxone plus Vancomycin along with an adjuvant which restricts the production of toxin by MRSA pathogens and is highly effective in combating Methicillin Resistant Staphylococcus Aureus (MRSA) along with other advantages of reduced treatment time, cost and adverse effects.

The Company has already been marketing Vancoplus successfully in India and few of the emerging markets across the globe. Venus Remedies' Baddi facility is already approved as per EU GMP for manufacturing of Vancoplus, which is in line with the Canadian Regulatory

## VENUS REMEDIES LIMITED

Corporate Office :  
51-52, Industrial Area, Phase-I,  
Panchkula (Hry.) 134113, India

Regd. Office :  
SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India

Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



Unit-I :  
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :  
Hill Top Industrial Estate, Jharmajra EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :  
VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany



authorities to market the drug.

Vancoplus is growing with a CAGR of 50% since past 3 years. Apart from Canada, the patent for this product has already been granted from USA, South Africa, New Zealand and Ukraine & Australia.

Yours faithfully,  
for VENUS REMEDIES LIMITED.

Ramanjit Kaur  
Assistant Manager  
Corporate Communication

## VENUS REMEDIES LIMITED

### Corporate Office :

51-52, Industrial Area, Phase-I,  
Panchkula (Hry.) 134113, India

### Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India

Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



### Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

### Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP Phase-I, (Extn.),  
Bharoli Kalan, Baddi (H.R.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

### Unit-V :

VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368 Wonna, Germany